Adrian Peter V, Bogaert Debby, Oprins Maartje, Rapola Satu, Lahdenkari Mika, Kilpi Terhi, de Groot Ronald, Käyhty Helena, Hermans Peter W M
Laboratory of Pediatrics/Room Ee1500, Erasmus MC-Sophia, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
Vaccine. 2004 Jul 29;22(21-22):2737-42. doi: 10.1016/j.vaccine.2004.01.042.
Surface associated pneumococcal proteins alpha-enolase (Eno), immunoglobulin A1 protease (Iga), streptococcal lipoprotein rotamase A (SlrA), and putative proteinase maturation protein A (PpmA) have potential as candidates for future protein-based anti-pneumococcal vaccines. The immunogenicity of these proteins were studied in a cohort of 329 children during their first two years of life. During the first recorded episode of otitis media, acute and convalescent phase sera were available from 151 children. Concentrations of antibodies against Eno, Iga, SlrA and PpmA were measured by EIA and detected in 99% (300/302), 95% (288/302), 95% (288/302), and 83% (251/302) of the sera, respectively. There were no statistically significant differences between the groups of children with and without a history of pneumococcal contact or with respect to the type of pneumococcal contact. Despite a mean overall decrease in the antibody titers in the convalescent sera following AOM, several children were able to respond with a more than twofold increase in antibody titer in response to AOM. The majority of the children with increased antibody concentrations appeared in the groups, which were colonized with pneumococci at the time of serum collection, but were recorded as having no prior contact with pneumococci. In conclusion, SlrA, PpmA, Eno and Iga are immunogenic proteins that elicit antibody responses early in life. No significant correlation between antibody titers to these proteins and pneumococcal carriage or infection was found. Presumably, this results from the presence of cross-reactive epitopes on commensal bacteria.
表面相关肺炎球菌蛋白α-烯醇化酶(Eno)、免疫球蛋白A1蛋白酶(Iga)、链球菌脂蛋白旋转异构酶A(SlrA)和假定的蛋白酶成熟蛋白A(PpmA)有潜力成为未来基于蛋白的抗肺炎球菌疫苗的候选物。在329名儿童生命的头两年对这些蛋白的免疫原性进行了研究。在首次记录的中耳炎发作期间,从151名儿童中获取了急性期和恢复期血清。通过酶免疫测定法测量了针对Eno、Iga、SlrA和PpmA的抗体浓度,分别在99%(300/302)、95%(288/302)、95%(288/302)和83%(251/302)的血清中检测到。有或没有肺炎球菌接触史的儿童组之间,或关于肺炎球菌接触类型方面,均无统计学上的显著差异。尽管急性中耳炎后恢复期血清中的抗体滴度总体平均下降,但有几名儿童对急性中耳炎的反应是抗体滴度增加两倍以上。抗体浓度增加的大多数儿童出现在血清采集时被肺炎球菌定植但记录为此前没有肺炎球菌接触史的组中。总之,SlrA、PpmA、Eno和Iga是能在生命早期引发抗体反应的免疫原性蛋白。未发现针对这些蛋白的抗体滴度与肺炎球菌携带或感染之间有显著相关性。推测这是由于共生菌上存在交叉反应表位所致。